Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

Michael J.  Morris

Consulting or Advisory Role - Advanced Accelerator Applications; Athenex; Bayer; Curium Pharma; Curium Pharma; Endocyte; Johnson & Johnson; ORIC Pharmaceuticals

Research Funding - Bayer (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Janssen (Inst); Progenics (Inst); Roche/Genentech (Inst); Sanofi (Inst)

Travel, Accommodations, Expenses - Endocyte; Fujifilm

Johann S.  De Bono

Employment - Institute of Cancer Research

Honoraria - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; BioExcel; Boehringer Ingelheim; Celgene; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Medivation; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex

Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex

Research Funding - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; CellCentric; Daiichi Sankyo; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Vertex

Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)

Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Cellcentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex

Kim N.  Chi

Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Roche

Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)

Karim  Fizazi

Honoraria - Astellas Pharma (Inst); Bayer; Janssen (Inst); Sanofi (Inst)

Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer; Bristol-Myers Squibb; Clovis Oncology; Curevac; ESSA (Inst); Janssen Oncology (Inst); Orion; Sanofi (Inst)

Travel, Accommodations, Expenses - Janssen; MSD

Ken  Herrmann

Leadership - SOFIE

Stock and Other Ownership Interests  - SOFIE

Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Bain Capital; Bayer; BTG; GE Healthcare; IPSEN; ITG (Inst); Novartis; ROTOP Pharmaka (Inst); Siemens Healthineers

Kambiz  Rahbar

Honoraria - Advanced Accelerator Applications/Novartis; Bayer; Sirtex Medical

Consulting or Advisory Role - ABX Advanced biochemical compounds; ABX-CRO; Advanced Accelerator Applications/Novartis; Bayer

Scott T.  Tagawa

Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clovis Oncology; Dendreon; Endocyte; Genentech; Genomic Health; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Seagen; Tolmar

Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)

Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi

(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics; Telix Pharmaceuticals

Luke T.  Nordquist

No Relationships to Disclose

Nitin  Vaishampayan

Honoraria - Bayer; Exelixis; Pfizer

Consulting or Advisory Role - Alkermes; Bayer; Bristol-Myers Squibb; Exelixis; Merck

Speakers' Bureau - Bristol-Myers Squibb; Exelixis

Research Funding - Bristol-Myers Squibb; Merck

Ghassan  El-Haddad

Stock and Other Ownership Interests  - Johnson & Johnson/Janssen

Consulting or Advisory Role - Curium Pharma; Oncoinvent

Patents, Royalties, Other Intellectual Property - Patent Title: Locking Brakes For Enteral Feeding Tube Retention Member Inventor: Ghassan Elias El-Haddad Patent number: 10,492,999 Issue Date: December 3, 2019 Assignee: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Chandler H.  Park

No Relationships to Disclose

Tomasz M.  Beer

Stock and Other Ownership Interests  - Arvinas; Salarius Pharmaceuticals

Consulting or Advisory Role - Arvinas; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Constellation Pharmaceuticals; GRAIL; Janssen; Myovant Sciences; Novartis; Pfizer; Sanofi; Tolero Pharmaceuticals

Research Funding - Alliance Foundation Trials (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Freenome (Inst); GRAIL (Inst); Harpoon Therapeutics (Inst); Janssen Research & Development (Inst); Medivation (Inst); Sotio (Inst); Theraclone Sciences (Inst); Zenith Epigenetics (Inst)

Wendy J  Pérez-Contreras

Employment - Endocyte; Novartis

Stock and Other Ownership Interests  - Novartis

Michelle  Desilvio

Employment - Novartis Pharmaceuticals UK Ltd.

Stock and Other Ownership Interests  - Novartis Pharmaceuticals UK Ltd.

Euloge E.  Kpamegan

Employment - Novartis

Stock and Other Ownership Interests  - Novartis

Germo  Gericke

No Relationships to Disclose

Richard Adam  Messmann

Employment - Novartis

Stock and Other Ownership Interests  - Novartis

Bernd J.  Krause

Research Funding - Advanced Accelerator Applications/Novartis (Inst)

A. Oliver  Sartor

Stock and Other Ownership Interests  - Abbvie; Cardinal Health; Clarity Pharmaceuticals; Clovis Oncology; GlaxoSmithKline; Lilly; Noria Therapeutics; PSMA Therapeutics; United Health Group

Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clarity Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Fusion Pharmaceuticals; Isotopen Technologien; Janssen; Myovant Sciences; Myriad Genetics; Noria Therapeutics; Novartis; Noxopharm; Pfizer; Point Biopharma; Progenics; Sanofi; Telix Pharmaceuticals; TeneoBio; Theragnostics

Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); InVitae (Inst); Janssen; Merck (Inst); Progenics; Sanofi (Inst); SOTIO

Expert Testimony - Sanofi

Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi